Stiripentol in Dravet Syndrome

• Status: No longer available
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Stiripentol

Criteria

Inclusion Criteria:

• Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures